A Phase I Open Label, Multicenter, Dose-Escalation, Multidose Study of MDX-1411 Administered Every 14 days in Subjects with Advanced or Recurrent Clear Cell Renal Carcinoma (Medarex Inc. MDX1411-01).

Trial Profile

A Phase I Open Label, Multicenter, Dose-Escalation, Multidose Study of MDX-1411 Administered Every 14 days in Subjects with Advanced or Recurrent Clear Cell Renal Carcinoma (Medarex Inc. MDX1411-01).

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2013

At a glance

  • Drugs MDX 1411 (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Planned number of patients changed from 40 to 41 as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Planned end date changed from 1 Sep 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top